SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc (VCYT). (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that at least 18 abstracts focused on its Decipher Prostate ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that 17 Decipher-focused abstracts will be presented at the 2025 ASCO ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc (VCYT). (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that eight abstracts featuring data derived from testing with ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced that new data from a large, population-based study reinforce the clinical utility of the Decipher Prostate ...
GenomeDx Biosciences today announced the publication of data demonstrating its Decipher™ test outperformed existing risk assessment tools for predicting metastatic prostate cancer in patients ...